8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Feb 6, 2026·SEC
Material company update
Jan 29, 2026·SEC
Anebulo Pharmaceuticals, Inc.(ANEB)Earnings, Financials & Key Ratios
ANEB•NASDAQ
$0.40
Price updated Jun 27, 2026
AboutAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.Show more
- Revenue$0
- EBITDA-$8M-0.6%
- Net Income-$8M-3.4%
- EPS (Diluted)-0.25+21.9%
- ROE-109.69%+3.6%
ANEB Price & Volume
Anebulo Pharmaceuticals, Inc. (ANEB) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Anebulo Liquidity Runway
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
"Anebulo Pharmaceuticals remains a pre-revenue biotechnology entity entirely dependent on external financing to fund its clinical development pipeline. The company faces significant financial pressure as its asset base has contracted to $9.4M, down from $15.8M in 2025Q2, while accumulating a $78.0M deficit in retained earnings. Investors should monitor the company's ability to reach critical regulatory milestones before its current cash reserves of $9.0M are exhausted, which may necessitate further dilutive capital raises."
Verdict Logic
the company's cash position of $9.0M against a quarterly operating loss of $2.6M suggests a limited runway that likely requires dilutive financing within the next twelve months.
ANEB Growth Metrics
Anebulo Pharmaceuticals, Inc. (ANEB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.24%
Return on Capital
10 Years-66.31%
5 Years-78.33%
3 Years-108.12%
Last Year-117.24%
Peers Comparison
Key metrics vs top competitors for Anebulo Pharmaceuticals, Inc. (ANEB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.40 | $16.11M | -1.58 | — | — | -109.69% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $6.05 | $5.47M | -0.81 | — | -6717.4% | -88.41% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — |
Compare ANEB vs Peers
Anebulo Pharmaceuticals, Inc. (ANEB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANEB SEC Filings & Documents
Anebulo Pharmaceuticals, Inc. (ANEB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANEB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANEB Frequently Asked Questions
Anebulo Pharmaceuticals, Inc. (ANEB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ANEB profitable?
Anebulo Pharmaceuticals, Inc. (ANEB) reported a net loss of $8.0M for fiscal year 2025.
Dividend & Returns
What is ANEB's return on equity?
Anebulo Pharmaceuticals, Inc. (ANEB) has a return on equity (ROE) of -109.7%. Negative ROE indicates the company is unprofitable.
What is Anebulo Pharmaceuticals, Inc.'s free cash flow?
Anebulo Pharmaceuticals, Inc. (ANEB) had negative free cash flow of $5.8M in fiscal year 2025, likely due to heavy capital investments.